Anatomical and Functional Outcomes after Endoresection and Adjuvant Ruthenium Brachytherapy for Uveal Melanoma: A Single-Center Experience.

Cinzia MazziniGiulio Vicini Laura Di Leo Daniela MassiStanislao RizzoFabrizio Giansanti

Published in: Life (Basel, Switzerland) (2023)

Endoresection and adjuvant Ru-106 brachytherapy is a valuable conservative option for selected UM patients and can be used both as a primary treatment and as a salvage therapy. It can control melanoma and avoid enucleation, reduce radiation-related complications, and provide tumor tissue for chromosomal analysis and prognostic testing.

Keyphrases

high dose
end stage renal disease
radiation therapy
early stage
ejection fraction
chronic kidney disease
newly diagnosed
peritoneal dialysis
risk factors
prognostic factors
stem cells
radiation induced
smoking cessation
patient reported outcomes
bone marrow
skin cancer
quantum dots
basal cell carcinoma